{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:42Z","timestamp":1792025202839,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma remains among the deadliest malignancies worldwide, and effective therapies are still lacking. Actinomycetota are among the richest microbial sources of bioactive secondary metabolites, and three agents in clinical use against pancreatic malignancy derive from them \u2014 streptozotocin, everolimus and doxorubicin \u2014 though all three are indicated for neuroendocrine rather than ductal tumors. This review provides a critical narrative synthesis of Actinomycetota-derived metabolites evaluated in pancreatic cancer models, with every potency value re-derived from the primary literature and interpreted alongside assay conditions and available mechanistic and in vivo evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>\n                      Fifty-two compounds from 25 primary reports encompass polyketides, nonribosomal peptides, depsipeptides, RiPPs, alkaloids, ionophores and hybrid scaffolds. Rather than a simple ranking of increasingly potent cytotoxins, the literature poses a sharper question about selectivity. Two compounds are conditionally active: kigamicin D only under nutrient deprivation and BE-43547A\n                      <jats:sub>2<\/jats:sub>\n                      only under hypoxia, exploiting the metabolic state that defines the disease rather than any intrinsic difference between malignant and normal cells. Both were recovered by screens built to detect that behavior, and neither has been shown to hold a therapeutic window in vivo. Separately, thiogochangamide B retains activity in gemcitabine-resistant models, while trienomycin A binds STAT3 directly, suppresses proliferation across eight pancreatic lines, achieves 84\u201398% tumor growth inhibition in xenografts at doses producing no detectable toxicity, and distributes preferentially to pancreatic tissue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Conditional activity is best read as a hypothesis about how such compounds should be sought rather than as an established route to selectivity. Despite remarkable chemical diversity, translation remains constrained by the limited use of normal-cell controls, predictive biomarkers and clinically relevant preclinical models. Screens conducted in nutrient-replete, normoxic monolayer culture will systematically miss compounds of this kind. Future efforts should prioritize compounds that exploit the metabolic liabilities of pancreatic cancer rather than pursuing greater cytotoxic potency.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01842-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:17Z","timestamp":1792022837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5660-524X","authenticated-orcid":false,"given":"Daynara da Silva Pereira","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8145-0435","authenticated-orcid":false,"given":"Marcelly da Silveira","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s da Rocha","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1992-2032","authenticated-orcid":false,"given":"Lucas Evangelista","family":"Lima Terceiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-7707","authenticated-orcid":false,"given":"Natanael Teles Ramos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8940-1988","authenticated-orcid":false,"given":"Genil Dantas","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-8747","authenticated-orcid":false,"given":"Thalisson Amorim","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-2249","authenticated-orcid":false,"given":"Valn\u00eas Silva","family":"Rodrigues-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-8692","authenticated-orcid":false,"given":"Samuel Paulo","family":"Cibulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1842_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"1842_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Groot Koerkamp B, Seufferlein T, Wilmink JW, Besselink MG. Pancreatic cancer. Lancet. 2025;405:1182\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2.","journal-title":"Lancet"},{"key":"1842_CR3","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0.","journal-title":"Lancet"},{"key":"1842_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21:7\u201324. https:\/\/doi.org\/10.1038\/s41575-023-00840-w.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1842_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod. 2020;83:770\u2013803. https:\/\/doi.org\/10.1021\/acs.jnatprod.9b01285.","journal-title":"J Nat Prod"},{"key":"1842_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: Advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u201316. https:\/\/doi.org\/10.1038\/s41573-020-00114-z.","journal-title":"Nat Rev Drug Discov"},{"key":"1842_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10295-015-1723-5","volume":"43","author":"L Katz","year":"2016","unstructured":"Katz L, Baltz RH. Natural product discovery: Past, present, and future. J Ind Microbiol Biotechnol. 2016;43:155\u201376. https:\/\/doi.org\/10.1007\/s10295-015-1723-5.","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"W1","key":"1842_CR8","doi-asserted-by":"publisher","first-page":"W46","DOI":"10.1093\/nar\/gkad344","volume":"51","author":"K Blin","year":"2023","unstructured":"Blin K, Shaw S, Augustijn HE, Reitz ZL, Biermann F, Alanjary M, Fetter A, Terlouw BR, Metcalf WW, Helfrich EJN, Weber T. antiSMASH 7.0: New and improved predictions for detection, regulation, chemical structures and visualisation. Nucleic Acids Res. 2023;51(W1):W46\u201350. https:\/\/doi.org\/10.1093\/nar\/gkad344.","journal-title":"Nucleic Acids Res"},{"key":"1842_CR9","doi-asserted-by":"publisher","first-page":"D586","DOI":"10.1093\/nar\/gkad984","volume":"52","author":"K Blin","year":"2024","unstructured":"Blin K, Shaw S, Medema MH, Weber T. The antiSMASH database version 4: Additional genomes and BGCs, new sequence-based searches and more. Nucleic Acids Res. 2024;52:D586\u20139. https:\/\/doi.org\/10.1093\/nar\/gkad984.","journal-title":"Nucleic Acids Res"},{"key":"1842_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.semcancer.2021.05.006","volume":"86","author":"CD Mohan","year":"2022","unstructured":"Mohan CD, Rangappa S, Nayak SC, Jadimurthy R, Wang L, Sethi G, Garg M, Rangappa KS. Bacteria as a treasure house of secondary metabolites with anticancer potential. Semin Cancer Biol. 2022;86:998\u20131013. https:\/\/doi.org\/10.1016\/j.semcancer.2021.05.006.","journal-title":"Semin Cancer Biol"},{"key":"1842_CR11","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.1007\/s00210-025-04001-5","volume":"398","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, Sarkar R. Unlocking the microbial treasure trove: Advances in Streptomyces-derived secondary metabolites in the battle against cancer. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:9971\u201310005. https:\/\/doi.org\/10.1007\/s00210-025-04001-5.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1842_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487\u2013505. https:\/\/doi.org\/10.1038\/s41575-020-0300-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1842_CR13","doi-asserted-by":"publisher","first-page":"189065","DOI":"10.1016\/j.bbcan.2023.189065","volume":"1879","author":"M Chakkera","year":"2024","unstructured":"Chakkera M, Foote JB, Farran B, Nagaraju GP. Breaking the stromal barrier in pancreatic cancer: Advances and challenges. Biochim Biophys Acta Rev Cancer. 2024;1879:189065. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189065.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1842_CR14","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.3390\/cancers16244260","volume":"16","author":"I Garajov\u00e1","year":"2024","unstructured":"Garajov\u00e1 I, Giovannetti E. Targeting perineural invasion in pancreatic cancer. Cancers. 2024;16:4260. https:\/\/doi.org\/10.3390\/cancers16244260.","journal-title":"Cancers"},{"key":"1842_CR15","doi-asserted-by":"publisher","first-page":"1421067","DOI":"10.3389\/fonc.2024.1421067","volume":"14","author":"Y Sun","year":"2024","unstructured":"Sun Y, Jiang W, Liao X, Wang D. Hallmarks of perineural invasion in pancreatic ductal adenocarcinoma: New biological dimensions. Front Oncol. 2024;14:1421067. https:\/\/doi.org\/10.3389\/fonc.2024.1421067.","journal-title":"Front Oncol"},{"key":"1842_CR16","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70412-6","volume":"15","author":"DP Ryan","year":"2014","unstructured":"Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. Lancet Oncol. 2014;15:e447\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(14)70412-6.","journal-title":"Lancet Oncol"},{"key":"1842_CR17","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022. https:\/\/doi.org\/10.1038\/nrdp.2016.22.","journal-title":"Nat Rev Dis Primers"},{"key":"1842_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.soc.2022.03.004","volume":"31","author":"T Muraki","year":"2022","unstructured":"Muraki T, Reid MD, Basturk O, Adsay V. Pathology of pancreatic cancer. Surg Oncol Clin N Am. 2022;31:399\u2013414. https:\/\/doi.org\/10.1016\/j.soc.2022.03.004.","journal-title":"Surg Oncol Clin N Am"},{"key":"1842_CR19","doi-asserted-by":"publisher","first-page":"103140","DOI":"10.1016\/j.ctrv.2026.103140","volume":"146","author":"N Fazio","year":"2026","unstructured":"Fazio N, Spada F, Benini L, Mulargiu C, Del Re M, Danesi R. Streptozotocin revisited: Pharmacological determinants supporting new scheduling strategies in neuroendocrine tumors. Cancer Treat Rev. 2026;146:103140. https:\/\/doi.org\/10.1016\/j.ctrv.2026.103140.","journal-title":"Cancer Treat Rev"},{"key":"1842_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","volume":"22","author":"SB Dreyer","year":"2025","unstructured":"Dreyer SB, Beer P, Hingorani SR, Biankin A. Improving outcomes of patients with pancreatic cancer. Nat Rev Clin Oncol. 2025;22:439\u201356. https:\/\/doi.org\/10.1038\/s41571-025-01019-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1842_CR21","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul JL, de la Gourgou-Bourgade S. Fouchardi\u00e8re C. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"key":"1842_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD von Hoff","year":"2013","unstructured":"von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin S, Ma WW, Saleh MN. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"1842_CR23","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/cancers13164012","volume":"13","author":"M Diab","year":"2021","unstructured":"Diab M, Almhanna K, Strosberg J. FOLFIRINOX in metastatic pancreatic cancer: A systematic review and meta-analysis. Cancers. 2021;13:4012. https:\/\/doi.org\/10.3390\/cancers13164012.","journal-title":"Cancers"},{"key":"1842_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jamaoncol.2023.0781","volume":"10","author":"T Conroy","year":"2023","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer. JAMA Oncol. 2023;10:657\u201365. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0781.","journal-title":"JAMA Oncol"},{"key":"1842_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc1391","volume":"4","author":"BP Toole","year":"2004","unstructured":"Toole BP, Hyaluronan. From extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528\u201339. https:\/\/doi.org\/10.1038\/nrc1391.","journal-title":"Nat Rev Cancer"},{"key":"1842_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/cas.12913","volume":"107","author":"N Sato","year":"2016","unstructured":"Sato N, Kohi S, Hirata K, Goggins M. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Sci. 2016;107:569\u201375. https:\/\/doi.org\/10.1111\/cas.12913.","journal-title":"Cancer Sci"},{"key":"1842_CR27","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ. HALO 109\u2013301 Investigators. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2020;38:3185\u201394. https:\/\/doi.org\/10.1200\/JCO.20.00590.","journal-title":"J Clin Oncol"},{"key":"1842_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735\u201347. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.021.","journal-title":"Cancer Cell"},{"key":"1842_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers9110157","volume":"9","author":"M Amrutkar","year":"2017","unstructured":"Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to gemcitabine. Cancers. 2017;9:157. https:\/\/doi.org\/10.3390\/cancers9110157.","journal-title":"Cancers"},{"key":"1842_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1101\/gad.2016111","volume":"25","author":"S Yang","year":"2011","unstructured":"Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell\u2019Antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011;25:717\u201329. https:\/\/doi.org\/10.1101\/gad.2016111.","journal-title":"Genes Dev"},{"key":"1842_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633\u20137. https:\/\/doi.org\/10.1038\/nature12138.","journal-title":"Nature"},{"key":"1842_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","volume":"524","author":"RM Perera","year":"2015","unstructured":"Perera RM, Stoykova S, Nicolay BN, Ross KN, Fitamant J, Boukhali M, Lengrand J, Deshpande V, Selig MK, Ferrone CR, Settleman J, Stephanopoulos G, Dyson NJ, Zoncu R, Ramaswamy S, Haas W, Bardeesy N. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015;524:361\u20135. https:\/\/doi.org\/10.1038\/nature14587.","journal-title":"Nature"},{"key":"1842_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MMBR.00019-15","volume":"80","author":"EA Barka","year":"2016","unstructured":"Barka EA, Vatsa P, Sanchez L, Gaveau-Vaillant N, Jacquard C, Klenk HP, Cl\u00e9ment C, Ouhdouch Y, van Wezel GP. Taxonomy, physiology, and natural products of Actinobacteria. Microbiol Mol Biol Rev. 2016;80:1\u201343. https:\/\/doi.org\/10.1128\/MMBR.00019-15.","journal-title":"Microbiol Mol Biol Rev"},{"key":"1842_CR34","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1093\/nar\/gkae523","volume":"52","author":"TS J\u00f8rgensen","year":"2024","unstructured":"J\u00f8rgensen TS, Mohite OS, Sterndorff EB, Alvarez-Arevalo M, Blin K, Booth TJ, Charusanti P, Faurdal D, Hansen T\u00d8, Nuhamunada M, Mourched AS, Palsson B\u00d8, Weber T. A treasure trove of 1034 actinomycete genomes. Nucleic Acids Res. 2024;52:7487\u2013503. https:\/\/doi.org\/10.1093\/nar\/gkae523.","journal-title":"Nucleic Acids Res"},{"key":"1842_CR35","doi-asserted-by":"publisher","first-page":"117317","DOI":"10.1016\/j.ejmech.2025.117317","volume":"286","author":"R Yi","year":"2025","unstructured":"Yi R, Shi Y, Cao X, Pan C, Actinomycetes. Treasure trove for discovering novel antibiotic candidates. Eur J Med Chem. 2025;286:117317. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117317.","journal-title":"Eur J Med Chem"},{"key":"1842_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7164\/antibiotics.56.1004","volume":"56","author":"S Kunimoto","year":"2003","unstructured":"Kunimoto S, Lu J, Esumi H, Yamazaki Y, Kinoshita N, Honma Y, Hamada M, Ohsono M, Ishizuka M, Takeuchi T. Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot. 2003;56:1004\u201311. https:\/\/doi.org\/10.7164\/antibiotics.56.1004.","journal-title":"J Antibiot"},{"key":"1842_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1349-7006.2004.tb03247.x","volume":"95","author":"J Lu","year":"2004","unstructured":"Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H, Kigamicin D. a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells\u2019 tolerance to nutrient starvation. Cancer Sci. 2004;95:547\u201352. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb03247.x.","journal-title":"Cancer Sci"},{"key":"1842_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ja.2006.29","volume":"59","author":"T Masuda","year":"2006","unstructured":"Masuda T, Ohba S, Kawada M, Osono M, Ikeda D, Esumi H, Kunimoto S. Antitumor effect of kigamicin D on mouse tumor models. J Antibiot. 2006;59:209\u201314. https:\/\/doi.org\/10.1038\/ja.2006.29.","journal-title":"J Antibiot"},{"key":"1842_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7164\/antibiotics.51.629","volume":"51","author":"K Yamaguchi","year":"1998","unstructured":"Yamaguchi K, Tsurumi Y, Suzuki K, Nagai K, Okumura K, Nakanishi S, Yamashita M, Okuhara M. Ansatrienins B1 and B2, new ansamycin antibiotics. J Antibiot. 1998;51:629\u201338. https:\/\/doi.org\/10.7164\/antibiotics.51.629.","journal-title":"J Antibiot"},{"key":"1842_CR40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1021\/acs.orglett.1c04032","volume":"24","author":"H Li","year":"2022","unstructured":"Li H, Chen S, Wang J, Zhang M, Wu W, Liu W, Sun P. Ansafurantrienins, unprecedented ansatrienin derivatives formed via photocatalytic intramolecular [3\u2009+\u20092] oxidative cycloaddition. Org Lett. 2022;24:592\u20136. https:\/\/doi.org\/10.1021\/acs.orglett.1c04032.","journal-title":"Org Lett"},{"issue":"12","key":"1842_CR41","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1261\/rna.2307710","volume":"16","author":"L Lindqvist","year":"2010","unstructured":"Lindqvist L, Robert F, Merrick W, Kakeya H, Fraser C, Osada H, Pelletier J. Inhibition of translation by cytotrienin A, a member of the ansamycin family. RNA. 2010;16(12):2404\u201313. https:\/\/doi.org\/10.1261\/rna.2307710.","journal-title":"RNA"},{"issue":"12","key":"1842_CR42","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/bph.15435","volume":"178","author":"QR He","year":"2021","unstructured":"He QR, Tang JJ, Liu Y, Chen ZF, Liu YX, Chen H, Li D, Yi ZF, Gao JM. The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. Br J Pharmacol. 2021;178(12):2496\u2013515. https:\/\/doi.org\/10.1111\/bph.15435.","journal-title":"Br J Pharmacol"},{"key":"1842_CR43","doi-asserted-by":"publisher","first-page":"40689","DOI":"10.1038\/srep40689","volume":"7","author":"H-L Yu","year":"2017","unstructured":"Yu H-L, Jiang S-H, Bu X-L, Wang J-H, Weng J-Y, Yang X-M, He K-Y, Zhang Z-G, Ao P, Xu J, Xu M-J. Structural diversity of anti-pancreatic cancer capsimycins identified in mangrove-derived Streptomyces xiamenensis 318 and post-modification via a novel cytochrome P450 monooxygenase. Sci Rep. 2017;7:40689. https:\/\/doi.org\/10.1038\/srep40689.","journal-title":"Sci Rep"},{"key":"1842_CR44","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1002\/anie.200806121","volume":"48","author":"C Hertweck","year":"2009","unstructured":"Hertweck C. The biosynthetic logic of polyketide diversity. Angew Chem Int Ed Engl. 2009;48:4688\u2013716. https:\/\/doi.org\/10.1002\/anie.200806121.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1842_CR45","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1096\/fj.201901237R","volume":"34","author":"SH Jiang","year":"2020","unstructured":"Jiang SH, Dong FY, Da LT, Yang XM, Wang XX, Weng JY, Feng L, Zhu LL, Zhang YL, Zhang ZG, Sun YW. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. FASEB J. 2020;34:3943\u201355. https:\/\/doi.org\/10.1096\/fj.201901237R.","journal-title":"FASEB J"},{"key":"1842_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00006676-199711000-00008","volume":"15","author":"O Kainuma","year":"1997","unstructured":"Kainuma O, Asano T, Hasegawa M, Kenmochi T, Nakagohri T, Tokoro Y, Isono K. Inhibition of pancreatic cancer cell growth by manumycin. Pancreas. 1997;15:379\u201383. https:\/\/doi.org\/10.1097\/00006676-199711000-00008.","journal-title":"Pancreas"},{"key":"1842_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1349-7006.1996.tb03146.x","volume":"87","author":"T Ito","year":"1996","unstructured":"Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa J, Yamazaki E, Ishiguro H, Matsuzawa Y. Suppression of human pancreatic cancer growth by manumycin. Jpn J Cancer Res. 1996;87:113\u20136. https:\/\/doi.org\/10.1111\/j.1349-7006.1996.tb03146.x.","journal-title":"Jpn J Cancer Res"},{"key":"1842_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/md12010491","volume":"12","author":"E Harunari","year":"2014","unstructured":"Harunari E, Imada C, Igarashi Y, Fukuda T, Terahara T, Kobayashi T. Hyaluromycin, a new hyaluronidase inhibitor of polyketide origin from marine Streptomyces sp. Mar Drugs. 2014;12:491\u2013507. https:\/\/doi.org\/10.3390\/md12010491.","journal-title":"Mar Drugs"},{"key":"1842_CR49","doi-asserted-by":"publisher","first-page":"9063087","DOI":"10.1155\/2016\/9063087","volume":"2016","author":"S Kohi","year":"2016","unstructured":"Kohi S, Sato N, Koga A, Hirata K, Harunari E, Igarashi Y. Hyaluromycin, a novel hyaluronidase inhibitor, attenuates pancreatic cancer cell migration and proliferation. J Oncol. 2016;2016:9063087. https:\/\/doi.org\/10.1155\/2016\/9063087.","journal-title":"J Oncol"},{"key":"1842_CR50","doi-asserted-by":"publisher","first-page":"e01208","DOI":"10.1128\/aem.01208-22","volume":"88","author":"G-L Ma","year":"2022","unstructured":"Ma G-L, Xin L, Liao Y, Chong Z-S, Candra H, Pang LM, Lee SQE, Gakuubi MM, Ng SB, Liang Z-X. Characterization of the biosynthetic gene cluster and shunt products yields insights into the biosynthesis of balmoralmycin. Appl Environ Microbiol. 2022;88:e01208\u201322. https:\/\/doi.org\/10.1128\/aem.01208-22.","journal-title":"Appl Environ Microbiol"},{"key":"1842_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1039\/C1NP00068C","volume":"29","author":"MK Kharel","year":"2012","unstructured":"Kharel MK, Pahari P, Shepherd MD, Tibrewal N, Nybo SE, Shaaban KA, Rohr J. Angucyclines: Biosynthesis, mode of action, new natural products, and synthesis. Nat Prod Rep. 2012;29:264\u2013325. https:\/\/doi.org\/10.1039\/C1NP00068C.","journal-title":"Nat Prod Rep"},{"key":"1842_CR52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/md15050144","volume":"15","author":"AF Bra\u00f1a","year":"2017","unstructured":"Bra\u00f1a AF, Sarmiento-Vizca\u00edno A, Osset M, P\u00e9rez-Victoria I, Mart\u00edn J, de Pedro N, de la Cruz M, D\u00edaz C, Vicente F, Reyes F, Garc\u00eda LA, Blanco G, Lobophorin K. a new natural product with cytotoxic activity produced by Streptomyces sp. M-207 associated with the deep-sea coral Lophelia pertusa. Mar Drugs. 2017;15:144. https:\/\/doi.org\/10.3390\/md15050144.","journal-title":"Mar Drugs"},{"key":"1842_CR53","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/01.cad.0000136886.72917.6f","volume":"15","author":"S Bassett","year":"2004","unstructured":"Bassett S, Urrabaz R, Sun D. Cellular response and molecular mechanism of antitumor activity by leinamycin in MiaPaCa human pancreatic cancer cells. Anticancer Drugs. 2004;15:689\u201396. https:\/\/doi.org\/10.1097\/01.cad.0000136886.72917.6f.","journal-title":"Anticancer Drugs"},{"key":"1842_CR54","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12864-019-6032-3","volume":"20","author":"Z Xu","year":"2019","unstructured":"Xu Z, Shen J, Hua S, Wan D, Chen Q, Han Y, Ren R, Liu F, Du Z, Guo X, Shi J, Zhi Q. High-throughput sequencing of circRNAs reveals novel insights into mechanisms of nigericin in pancreatic cancer. BMC Genomics. 2019;20:716. https:\/\/doi.org\/10.1186\/s12864-019-6032-3.","journal-title":"BMC Genomics"},{"key":"1842_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7164\/antibiotics.55.1","volume":"55","author":"Y Uchihata","year":"2002","unstructured":"Uchihata Y, Ando N, Ikeda Y, Kondo S, Hamada M, Umezawa K. Isolation of a novel cyclic hexadepsipeptide pipalamycin from Streptomyces as an apoptosis-inducing agent. J Antibiot. 2002;55:1\u20137. https:\/\/doi.org\/10.7164\/antibiotics.55.1.","journal-title":"J Antibiot"},{"key":"1842_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"1842_CR57","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/jo991314b","volume":"65","author":"K Umezawa","year":"2000","unstructured":"Umezawa K, Ikeda Y, Uchihata Y, Naganawa H, Kondo S. Chloptosin, an apoptosis-inducing dimeric cyclohexapeptide produced by Streptomyces. J Org Chem. 2000;65:459\u201363. https:\/\/doi.org\/10.1021\/jo991314b.","journal-title":"J Org Chem"},{"key":"1842_CR58","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1021\/jo981512n","volume":"64","author":"K Umezawa","year":"1999","unstructured":"Umezawa K, Nakazawa K, Ikeda Y, Naganawa H, Kondo S. Polyoxypeptins A and B produced by Streptomyces: Apoptosis-inducing cyclic depsipeptides containing the novel amino acid (2S,3R)-3-hydroxy-3-methylproline. J Org Chem. 1999;64:3034\u20138. https:\/\/doi.org\/10.1021\/jo981512n.","journal-title":"J Org Chem"},{"key":"1842_CR59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2180-14-30","volume":"14","author":"Y Du","year":"2014","unstructured":"Du Y, Wang Y, Huang T, Tao M, Deng Z, Lin S. Identification and characterization of the biosynthetic gene cluster of polyoxypeptin A, a potent apoptosis inducer. BMC Microbiol. 2014;14:30. https:\/\/doi.org\/10.1186\/1471-2180-14-30.","journal-title":"BMC Microbiol"},{"key":"1842_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.7164\/antibiotics.50.659","volume":"50","author":"Y Sakai","year":"1997","unstructured":"Sakai Y, Yoshida T, Tsujita T, Ochiai K, Agatsuma T, Saitoh Y, Tanaka F, Akiyama T, Akinaga S, Mizukami T. GE3, a novel hexadepsipeptide antitumor antibiotic, produced by Streptomyces sp. I. Taxonomy, production, isolation, physico-chemical properties, and biological activities. J Antibiot. 1997;50:659\u201364. https:\/\/doi.org\/10.7164\/antibiotics.50.659.","journal-title":"J Antibiot"},{"key":"1842_CR61","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41401-024-01461-y","volume":"46","author":"C Liu","year":"2025","unstructured":"Liu C, Liu C, Liu G-J, Wang M-M, Jiao Y, Sun Y-J, Guo H, Wang L, Lu Y-X, Chen Y, Ding Y-H. BE-43547A2 exerts hypoxia-selective inhibition on human pancreatic cancer cells through targeting eEF1A1 and disrupting its association with FoxO1. Acta Pharmacol Sin. 2025;46:1433\u201344. https:\/\/doi.org\/10.1038\/s41401-024-01461-y.","journal-title":"Acta Pharmacol Sin"},{"key":"1842_CR62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1021\/acs.jnatprod.2c00902","volume":"86","author":"W Wang","year":"2023","unstructured":"Wang W, Kim S, Vu THN, Quach NT, Oh E, Park KH, Park C, Cho Y, Jang H, Roh E, Lee J, Kang E, Han SJ, Phi QT, Kang H. Bioactive piperazic acid-bearing cyclodepsipeptides, lydiamycins E\u2013H, from an endophytic Streptomyces sp. associated with Cinnamomum cassia. J Nat Prod. 2023;86:751\u20138. https:\/\/doi.org\/10.1021\/acs.jnatprod.2c00902.","journal-title":"J Nat Prod"},{"key":"1842_CR63","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1021\/acs.jnatprod.3c01275","volume":"87","author":"W Wang","year":"2024","unstructured":"Wang W, Lee J, Roh E, Shetye G, Cao J, McAlpine J, Pauli G, Franzblau S, Vu THN, Quach NT, Oh E, Park K-H, Park C, Cho Y, Jang H, Han SJ, Kim H, Cho S, Phi Q-T, Kang H. Cavomycins A\u2013C, linear oligomer depsipeptides from an annelid-associated Streptomyces cavourensis. J Nat Prod. 2024;87:976\u201383. https:\/\/doi.org\/10.1021\/acs.jnatprod.3c01275.","journal-title":"J Nat Prod"},{"key":"1842_CR64","doi-asserted-by":"publisher","first-page":"e17849","DOI":"10.1002\/advs.202517849","volume":"13","author":"YE Du","year":"2026","unstructured":"Du YE, Bae ES, Bui TTM, Lee SB, Kim D, Park J-G, Park Y, Park SY, Kang S, Lee B, Shin D, Kang YP, Lee I-G, Kim D-D, Kim S, Hong S, Moon K, Lee SK, Oh D-C. Metabologenomic hallmark-based discovery of bacterial thioamides as a new lead against drug-resistant pancreatic cancer. Adv Sci (Weinh). 2026;13:e17849. https:\/\/doi.org\/10.1002\/advs.202517849.","journal-title":"Adv Sci (Weinh)"},{"key":"1842_CR65","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1021\/ol300806e","volume":"14","author":"E Pan","year":"2012","unstructured":"Pan E, Jamison M, Yousufuddin M, MacMillan JB, Ammosamide D. an oxidatively ring opened ammosamide analog from a marine-derived Streptomyces variabilis. Org Lett. 2012;14:2390\u20133. https:\/\/doi.org\/10.1021\/ol300806e.","journal-title":"Org Lett"},{"key":"1842_CR66","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/ol702668x","volume":"10","author":"CC Hughes","year":"2008","unstructured":"Hughes CC, Prieto-D\u00e1vila A, Jensen PR, Fenical W. The ammosamides: Structures of cell cycle modulators from a marine-derived Streptomyces sp. Org Lett. 2008;10:629\u201331. https:\/\/doi.org\/10.1021\/ol702668x.","journal-title":"Org Lett"},{"key":"1842_CR67","doi-asserted-by":"publisher","first-page":"12978","DOI":"10.1021\/acs.jmedchem.0c01271","volume":"63","author":"J Wang","year":"2020","unstructured":"Wang J, Jin W, Zhou X, Li J, Xu C, Ma Z, Wang J, Qin L, Zhou B, Ding W, Gao T, Yao H, Chen Z. Identification, structure\u2013activity relationships of marine-derived indolocarbazoles, and a dual PKC\u03b8\/\u03b4 inhibitor with potent antipancreatic cancer efficacy. J Med Chem. 2020;63:12978\u201391. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01271.","journal-title":"J Med Chem"},{"key":"1842_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/md15090271","volume":"15","author":"A Sarmiento-Vizca\u00edno","year":"2017","unstructured":"Sarmiento-Vizca\u00edno A, Bra\u00f1a AF, P\u00e9rez-Victoria I, Mart\u00edn J, de Pedro N, de la Cruz M, D\u00edaz C, Vicente F, Acu\u00f1a JL, Reyes F, Garc\u00eda LA, Blanco G, Paulomycin G. a new natural product with cytotoxic activity against tumor cell lines produced by deep-sea sediment derived Micromonospora matsumotoense M-412 from the Avil\u00e9s Canyon in the Cantabrian Sea. Mar Drugs. 2017;15:271. https:\/\/doi.org\/10.3390\/md15090271.","journal-title":"Mar Drugs"},{"key":"1842_CR69","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/molecules27238367","volume":"27","author":"M Naeem","year":"2022","unstructured":"Naeem M, Basha FZ, Nawaz I, Shafique M, Shah SAA, Firdous S. Natural products as anticancer agents: Current status and future perspectives. Molecules. 2022;27:8367. https:\/\/doi.org\/10.3390\/molecules27238367.","journal-title":"Molecules"},{"key":"1842_CR70","doi-asserted-by":"publisher","first-page":"1550516","DOI":"10.3389\/fmicb.2025.1550516","volume":"16","author":"SA Hassan","year":"2025","unstructured":"Hassan SA, Sun R, Guo F, Zhang Y, Shao H, Yang X, Wang C, Yang C. Biological activity of secondary metabolites of actinomycetes and their potential sources as antineoplastic drugs: A review. Front Microbiol. 2025;16:1550516. https:\/\/doi.org\/10.3389\/fmicb.2025.1550516.","journal-title":"Front Microbiol"},{"key":"1842_CR71","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1016\/j.apsb.2022.08.022","volume":"12","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, Kong L, Xu Q, Ma H, Sun Y. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharm Sin B. 2022;12:4011\u201339. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.022.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"1842_CR72","doi-asserted-by":"publisher","first-page":"e015","DOI":"10.48130\/targetome-0026-0015","volume":"2","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Zhang J, Tu P, Zeng K, Wang L. Recent advances in the target identification strategies of natural products: An overview from 2014 to 2025. Targetome. 2026;2(2):e015. https:\/\/doi.org\/10.48130\/targetome-0026-0015.","journal-title":"Targetome"},{"key":"1842_CR73","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/biomedicines11030890","volume":"11","author":"E Sereti","year":"2023","unstructured":"Sereti E, Papapostolou I, Dimas K. Pancreatic cancer organoids: An emerging platform for precision medicine? Biomedicines. 2023;11:890. https:\/\/doi.org\/10.3390\/biomedicines11030890.","journal-title":"Biomedicines"},{"key":"1842_CR74","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3390\/cancers17233850","volume":"17","author":"F Morceau","year":"2025","unstructured":"Morceau F, El-Khoury V, Lee K, Berna MJ, Kwon YJ. Pancreatic cancer organoids: Modeling disease and guiding therapy. Cancers. 2025;17:3850. https:\/\/doi.org\/10.3390\/cancers17233850.","journal-title":"Cancers"},{"key":"1842_CR75","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3390\/cancers15072169","volume":"15","author":"VB Joshi","year":"2023","unstructured":"Joshi VB, Gutierrez Ruiz OL, Razidlo GL. The cell biology of metastatic invasion in pancreatic cancer: Updates and mechanistic insights. Cancers. 2023;15:2169. https:\/\/doi.org\/10.3390\/cancers15072169.","journal-title":"Cancers"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01842-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01842-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:19Z","timestamp":1792022839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01842-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01842-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"12 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"102"}}